• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
#

Pharmaceutical Companies

: 153
The company plans to use the proceeds to advance its lead drug candidate, which is in early trials in patients with moderate or severe atopic dermatitis / Photo: Unsplash/Testalize.me
Small Caps·
+1
·09.10.2026 15:00
TRex Bio IPO: LLY-backed biotech focused on autoimmune, inflammatory diseases debuts
  • TRXB
  • LLY
  • PFE
  • JNJ
Citis new price target for Moderna shares suggests a 60% drop in the pharmaceutical companys stock price / Photo: Dmitriy Melnikov / Shutterstock
News·30.09.2026 21:35
Moderna's Stock Rally Was "Excessive": Why a Citi Analyst Expects It to Fall 60%
  • MRNA
Iovance shares surged after the biotech raised its full-year revenue guidance, thanks to rising demand for a pair of melanoma treatments / Photo: Iovance Biotherapeutics
Small Caps·30.09.2026 16:39
Iovance rises by a third as strong melanoma drug demand drives revenue guidance bump
  • IOVA
Novo is expanding its portfolio of drugs to better compete with Eli Lilly / Photo: Novo
News·29.09.2026 13:38
Novo licensed a Chinese weight-loss pill for $2.6 billion. What makes it unique?
  • NVO
  • NOVO-B.CO
  • 1276.HK
  • 600276.SS
  • +1
Viking Therapeutics soared last week after the latest data for its GLP-1 therapy / Photo: Facebook/Nasdaq
Small Caps·28.09.2026 17:40
Motley Fool analyst calls Viking 'fantastic buy' for risk-tolerant investors
  • VKTX
  • LLY
Viking has been developing its own candidate for obesity and type 2 diabetes, VK2735 / Photo: Shutterstock.com / Faizal Ramli
Small Caps·
+1
·22.09.2026 21:39
Viking Therapeutics soars 31% intraday on upbeat data for its obesity shot
  • VKTX
  • LLY
The maker of Ozempic, Novo, may address the issue of hair loss / Photo: novonordisk.com
News·22.09.2026 20:10
The manufacturer of Ozempic is considering entering the hair loss treatment market
  • NVO
  • NOVO-B.CO
Novo disappointed investors who were expecting more concrete plans for turning the business around / Photo: novonordisk.com
News·21.09.2026 18:14
Novo's stock plummeted despite sales plans in the billions. What went wrong?
  • NVO
  • NOVO-B.CO
Definium went public in 2025 as MindMed, after which, in January 2026, it changed its name / Photo: X/Definium Therapeutics
Small Caps·15.09.2026 17:30
Biotech Definium reports another phase III success for anxiety disorder therapy
  • DFTX
Novo Nordisk to Shorten Its Name to Compete with Eli Lilly / Photo: novonordisk.com
News·14.09.2026 16:12
Novo Nordisk will shorten its name and change its logo. Will this help revitalize the business?
  • NVO
  • NOVO-B.CO
Shares of Swiss pharmaceutical giant Novartis plummeted 10% during trading on September 8 / Photo: Dmitriy Melnikov / Shutterstock.com
News·08.09.2026 16:07
Pharmaceutical giant Novartis is on track for its worst slump in six years following a series of failed trials
  • NOVN.SW
  • AMGN
A Rothschild analyst deemed the markets reaction to the results of Modernas skin cancer vaccine trials to be excessive / Photo: Shutterstock.com / Panaceum Media
News·03.09.2026 23:46
An analyst called Moderna's stock overvalued after it rose 400% since the start of the year
  • MRNA
Load more
X-channel

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026